AbbVie Inc. is 56.0x more valuable than TG THERAPEUTICS, INC. by market capitalization ($399.47 B vs $7.14 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TGTX | ABBV |
|---|---|---|
| Market cap | $7.14 B | $399.47 B |
| US-listed rank | #1140 | #28 |
| Revenue (latest FY) | $616.29M | $61.16B |
| Net income (latest FY) | $447.20M | $4.23B |
| Net margin | 72.6% | 6.9% |
| P/E (trailing FY) | 16.0 | 94.5 |
| SEC filings | 1,133 | 1,008 |
AbbVie Inc. is 56.0x more valuable than TG THERAPEUTICS, INC. by market capitalization ($399.47 B vs $7.14 B).
In their latest fiscal years, TG THERAPEUTICS, INC. reported $616.29M in revenue while AbbVie Inc. reported $61.16B.
Full pages: TG THERAPEUTICS, INC. and AbbVie Inc., or browse the full rankings.